Desonide and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Desonide (desonide) and Jakafi (ruxolitinib phosphate). Common drug interactions include haematoma among females and cardiomyopathy among males.

The phase IV clinical study analyzes what interactions people have when they take Desonide and Jakafi. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Desonide?

Desonide has active ingredients of desonide. It is often used in rosacea. eHealthMe is studying from 5,484 Desonide users. Check the latest studies of Desonide.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

26 people who take Desonide and Jakafi together, and have interactions are studied.

What are the common drug interactions of Desonide and Jakafi, by gender? *:

female:

Haematoma (collection of blood outside the blood vessels)
Haemoglobin decreased
Haemorrhage (bleeding)
International normalised ratio increased
Pain in extremity
Slow response to stimuli (slow response by nerves)
Somnolence (a state of near-sleep, a strong desire for sleep)
Urinary tract infection
Neuralgia (pain in one or more nerves)
Night sweats (sweating in night)

male:

Cardiomyopathy (weakening of the heart muscle)
Diarrhoea
Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells)
Thrombosis (formation of a blood clot inside a blood vessel)

What are the common drug interactions of Desonide and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells)

50-59:

n/a

60+:

Cardiomyopathy (weakening of the heart muscle)
Contusion (a type of hematoma of tissue in which capillaries)
Urinary tract infection
Fatigue (feeling of tiredness)
Haematoma (collection of blood outside the blood vessels)
Haemoglobin decreased
Haemorrhage (bleeding)
International normalised ratio increased
Pain in extremity
Slow response to stimuli (slow response by nerves)

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 3 people, 11.54%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 7.69%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Desonide and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously